World's Best Scientists 2026 revealed!
Anne Hagemeijer

Anne Hagemeijer

D-Index & Metrics

Medicine

D-Index
85
Citations
25351
World Ranking
14654
National Ranking
185

Overview

Anne Hagemeijer is affiliated with KU Leuven in Belgium, focusing on research primarily within the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work encompasses several subfields including Hematology, Molecular Biology, Cancer Research, and Public Health, Environmental and Occupational Health.

The researcher has contributed to studies related to multiple main topics, notably Acute Myeloid Leukemia Research, Epigenetics and DNA Methylation, Cancer Genomics and Diagnostics, Multiple Myeloma Research and Treatments, Acute Lymphoblastic Leukemia research, and RNA modifications and cancer.

Recent publications authored or co-authored by Anne Hagemeijer include:

  • Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients (2021, Clinical Epigenetics)
  • Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia (2020, Annals of Hematology)
  • Correction to: Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients (2021, Clinical Epigenetics)

The frequent co-authors collaborating with Anne Hagemeijer include Dietmar Pfeifer, Gabriele Ihorst, Uwe Platzbecker, Michael Lübbert, and Julia Stomper.

Publication outlets where Anne Hagemeijer's work commonly appears are Clinical Epigenetics and Annals of Hematology. Clinical Epigenetics hosts two of their recent publications, while Annals of Hematology features another.

Best Publications

  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

    Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer

  • The Apoptosis Inhibitor Gene API2 and a Novel 18q Gene,MLT, Are Recurrently Rearranged in the t(11;18)(q21;q21) Associated With Mucosa-Associated Lymphoid Tissue Lymphomas

    Judith Dierlamm;Mathijs Baens;Iwona Wlodarska;Margarita Stefanova-Ouzounova

  • Translocation of c- abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

    Claus R. Bartram;Annelies de Klein;Anne Hagemeijer;Ton van Agthoven

  • Acquired mutations in TET2 are common in myelodysplastic syndromes

    Saskia M C Langemeijer;Roland P Kuiper;Marieke Berends;Ruth Knops

  • Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype

    Dimitri A. Breems;Wim L. J. Van Putten;Georgine E. De Greef;Shama L. Van Zelderen-Bhola

  • Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

    Michael Lübbert;Stefan Suciu;Liliana Baila;Björn Hans Rüter

  • Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

    Maria Debiec-Rychter;Jan Cools;Herlinde Dumez;Raf Sciot

  • Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia

    C Graux;Jan Cools;C Melotte;H Quentmeier

  • Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

    Stefan Suciu;Franco Mandelli;Theo de Witte;Robert Zittoun

  • Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

    M. Debiec-Rychter;H. Dumez;I. Judson;B. Wasag

  • Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.

    B. Löwenberg;S. Suciu;E. Archimbaud;H. Haak

  • Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

    Sergio Amadori;Stefan Suciu;Dominik Selleslag;Franco Aversa

  • Myeloid cell differentiation arrest by miR-125b-1 in myelodysplasic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation

    Marina Bousquet;Cathy Quelen;Roberto Rosati;Véronique Mansat-De Mas;Véronique Mansat-De Mas

  • Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.

    Carlos Graux;Jan Cools;Lucienne Michaux;Peter Vandenberghe

  • Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.

    Jan Cools;Iwona Wlodarska;Riet Somers;Nicole Mentens

  • Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity

    Maria Debiec-Rychter;Bartosz Wasag;Michel Stul;Ivo De Wever

  • A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

    Michael Lübbert;Björn H. Rüter;Rainer Claus;Claudia Schmoor

  • A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements.

    Danielle Sainty;Vincenzo Liso;Angelo Cantù-Rajnoldi;David Head

  • Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias

    P Vandenberghe;I Wlodarska;L Michaux;P Zachée

  • Hu-ets-1 and Hu-ets-2 genes are transposed in acute leukemias with (4;11) and 8;21) translocations

    N. Sacchi;D. K. Watson;A. H. M. Guerts Van Kessel;A. Hagemeijer

Frequent Co-Authors

Peter Marynen
Peter Marynen KU Leuven
Jan Cools
Jan Cools KU Leuven
Stefan Suciu
Stefan Suciu European Organisation for Research and Treatment of Cancer
Theo de Witte
Theo de Witte Radboud University
Sergio Amadori
Sergio Amadori University of Rome Tor Vergata

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA isn’t the only route to a rewarding healthcare career. Thanks to online learning, students can explore various fast-track and advanced nursing programs that offer flexible study options and streamlined pathways into the field.

For those already holding a Master of Science in Nursing (MSN), the shortest msn to dnp program options allow for direct progression toward a Doctor of Nursing Practice (DNP) degree in less time. If you’re looking to balance work and study, dnp online programs provide flexible scheduling along with rigorous preparation for advanced roles.

Entry-level candidates might consider fast track lpn programs to quickly become a Licensed Practical Nurse, which can be a strong foundation for further studies. Those interested in mental health fields can benefit from accelerated msn psychiatric np programs designed to fast-track qualified nurses into psychiatric nurse practitioner roles.

Exploring these pathways can help you find a degree or career track that fits your needs—whether you are looking to upgrade your credentials or start a new journey in healthcare.

Best Scientists Citing Anne Hagemeijer

Trending Scientists